RxDoctor Payments Data

Deepak Gupta, MD

Cardiovascular Disease · Nashville, TNNPI 1588822803

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,819 of the $13,042 with a category attached, or 90.6%. Novo Nordisk accounts for 99.7% of it on its own, with 1 other manufacturer making up the rest.

$13,042in general payments, 2019–2025

Across 8 payments — averaging $1630.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$13K
  • Johnson & Johnson$45
$41,888in research payments, 2019–2025

Across 17 payments — averaging $2464.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$23K
  • Medtronic$17K
  • Siemens Medical Solutions USA, Inc.$2K
  • Novartis$8

What the payments were for

  • Consulting fees$11,81991%
  • Travel & lodging$1,0578%
  • Food & beverage$1341%
  • Education$320%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$12,997
Johnson & Johnson1$45

How this compares

$13,042 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee →

Medicare billing

Part B allowed, 2024
$33,630
Medicare patients
826
Services billed
1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin48$57,263
EliquisApixaban39$34,249
FarxigaDapagliflozin Propanediol20$25,928
EntrestoSacubitril/Valsartan14$18,016
WegovySemaglutide11$17,948
XareltoRivaroxaban13$13,940
Potassium Chloride79$6,034
Bumetanide21$1,987
Torsemide82$1,956
Ranolazine ErRanolazine13$858
Metoprolol Succinate42$682
Droxidopa12$613
Atorvastatin Calcium47$495
Ezetimibe28$463
Spironolactone62$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskWegovy$12,997$17,94811 claims
Johnson & JohnsonXarelto$45$13,94013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →